Stockreport

The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF - Results published in first paper from 18-month analysis of ongoing pivotal Phase 3 trial were generally consistent with overall efficacy and safety data reported in pr [Read more]